← Coverage
INSM Insmed
Biotech · NASDAQ · 한국어 페이지
ARIKAYCE and brensocatib. Drug HS codes are too broad for a useful trade proxy.
Current-quarter revenue estimate
Quarter ending Dec 2026 · report date not set
Our estimate
$972M
$699M–$1.25B
vs a year ago
+268%
vs consensus
+70%
Estimate · within ±5% in 4 of 12 backtested quarters, average error 13.4%. Model: company guidance adjusted by its historical beat rate.
Key supply-chain flow
No monthly flow with enough history.
Mapped data flows
How each flow moves with quarterly revenue (year-over-year correlation, flow leading by 0–2 quarters).
| Flow | Stage | Revenue link | Correlation | Data to |
|---|
A ≥0.7 direct link · B ≥0.5 linked · C ≥0.3 industry context · D weak. Fewer than 8 comparable quarters caps the grade at C.
Scorecard
Our last estimate before each report vs actual revenue.
| Quarter | Our estimate | Actual | Error |
|---|---|---|---|
| Sep 2026 | $564M | $524M | +7.5% |